Posts
The Knowledge Toll
How Academic Publishers Captured the Distribution of Publicly Funded Science — and What It Costs Everyone Else
The Lobby
RELX — Elsevier's parent company — spends approximately $3 million annually in United States federal lobbying. The 2012 House Science Committee hearing named Elsevier's 37% operating margins explicitly on the record. No legislation resulted. The Research Works Act, introduced the same year with industry backing, would have prohibited federal agencies from requiring open access to publicly funded research. It was withdrawn — but introduced. This post documents the four instruments through which the industry has defended the toll against three decades of reform pressure, and what the architecture looks like now that the NIH mandate has finally landed.
The sticky note in the image at the top of this series says: Check Interlibrary Loan. It was written by someone who had been to that terminal before, who had encountered that paywall before, who had learned the workaround and left it for the next person. It is the human trace of an architecture that has operated for fifty years — the institutional residue of a toll that has survived every reform attempt mounted against it, adapted to every regulatory pressure applied to it, and maintained a 34.8% operating margin through decades in which the cost of distributing digital information fell to near zero.
RELX spends approximately $3 million annually in United States federal lobbying, classified primarily under "Printing and Publishing." That figure does not include political contributions, state-level lobbying, trade association dues to the Association of American Publishers and the International Association of Scientific, Technical and Medical Publishers, or the informal influence that comes from being the company whose journals determine whether scientists get hired, tenured, and funded at the institutions that train the policymakers who would regulate them.
The $3 million is not the measure of the lobby. It is its visible surface.
The Four Defense Instruments
The Research Works Act: The Lobby's Most Visible Moment
In December 2011, Representatives Darrell Issa and Carolyn Maloney introduced the Research Works Act, H.R. 3699. The bill would have prohibited federal agencies from requiring open access to the results of federally funded research — explicitly nullifying the NIH's 2008 public access policy and preempting any future agency mandates. The legislative language was drafted with industry input. Its effect, if enacted, would have been to permanently protect the commercial publishing toll from federal regulatory challenge.
The bill was withdrawn in February 2012, following a widely publicized academic boycott of Elsevier — the Cost of Knowledge campaign, in which thousands of researchers pledged to refuse to submit to, review for, or serve on editorial boards of Elsevier journals. The boycott was organized online and attracted over 12,000 signatories within weeks. It created sufficient political cost to make the bill's continued advancement untenable.
The Research Works Act's withdrawal is frequently cited as a victory for open access advocates. FSA analysis notes what it actually was: a test of the lobby's reach, conducted in a political environment where the academic community's response was unusually organized and rapid. The bill was introduced. It had congressional sponsors. It reflected the industry's preferred outcome clearly enough to be introduced under its own name. Its withdrawal reflected the force of the opposition, not the absence of the industry's ambition.
The 2012 Hearing: Named and Ignored
In March 2012, the House Committee on Science, Space, and Technology held a hearing on federally funded research and public access. Witnesses included publishing industry representatives, open access advocates, and academic librarians. In the course of that hearing, Elsevier's operating margins — at the time approximately 37% — were named explicitly on the record, in a congressional forum, by witnesses arguing that the industry's profit levels were incompatible with its claim that subscription revenue was necessary to fund essential publishing infrastructure.
No legislation resulted. The hearing produced a record, a transcript, and a documented moment in which a congressional committee heard that the world's largest academic publisher earned operating margins exceeding Apple's — from selling publicly funded research back to the public institutions that produced it — and chose not to act. That choice is as architecturally significant as any lobbying expenditure. The instrument that defends the toll most effectively is not the $3 million in annual lobbying. It is the sustained absence of political will to act on evidence that has been in the public record for over a decade.
The Adaptation Cycle: How the Toll Changes Form
The academic publishing industry has demonstrated, across thirty years of open access pressure, a consistent capacity to adapt the form of its revenue instruments without reducing their substance. The serials crisis of the 1980s and 1990s produced the Big Deal — a structure that locked institutions into expanded packages while maintaining price escalation. The open access movement of the 2000s produced the APC — a fee that shifted the payment point from reader to author while preserving commercial publisher revenue. The funder mandate pressure of the 2010s produced the transformative agreement — a structure that appeared to be transitioning toward open access while preserving revenue streams. Each adaptation was named as reform. Each preserved the toll.
cOAlition S ended its support for transformative agreements in December 2024, explicitly naming the pattern. The current adaptation — which is already visible in publisher communications and contract negotiations — is the "read and publish" agreement rebranded as a "research support" or "institutional membership" model, in which universities pay a single annual fee covering both reading rights and unlimited open access publishing for their researchers. The fee is typically higher than the prior subscription, justified by the open access publishing component. The publisher continues to collect from the institution. The collection mechanism has been renamed.
The NIH zero-embargo mandate is the first regulatory instrument that is genuinely difficult for the publishers to adapt around in the same way. The Government Use License is a pre-existing federal right embedded in grant agreements — it cannot be negotiated away in a publishing contract, because the author does not have the right to waive it. The mandate does not require author action beyond deposit. It does not depend on publisher cooperation. It does not require an APC. The publisher's version of record remains behind the paywall; the accepted manuscript is simultaneously freely available. For the first time, the toll and the bypass coexist on equal terms at the moment of publication — and the bypass is free.
What This Series Has Established
Four posts have traced the knowledge toll from its architectural foundation through its institutional lock, its counter-architecture, and the lobby that has sustained it against three decades of reform pressure.
The architecture is a public investment to private enclosure chain: NIH funds the research, the university pays the salary, the author writes for free, the peer reviewer validates for free, and Elsevier distributes the result at a 34.8% operating margin by owning the journal brands that determine scientific careers. The Big Deal bundle locks institutions into packages that make cancellation economically irrational regardless of whether individual journals merit their cost. The NDA suppresses the price transparency that would allow collective negotiation. The APC extends the extraction to the open access channel. The impact factor ensures that career incentives keep scientists submitting to commercial journals rather than the free alternatives that have operated for thirty-three years.
The counter-architecture exists and functions: arXiv at $2 million per year, bioRxiv and medRxiv expanding into life sciences, Plan S ending its support for the industry's preferred adaptation instrument, and the NIH zero-embargo mandate making every NIH-funded paper simultaneously available at no cost from July 2025 onward.
The toll has not fallen. It collects 34.8% margins from the distribution of knowledge produced at public expense, defended by a lobby that spends $3 million annually in federal lobbying, an impact factor system that makes the toll professionally mandatory for scientists regardless of their preferences, and a congressional record of named evidence and absent response.
The sticky note still says: Check Interlibrary Loan. The terminal still says: Access Denied. The stack of papers beside it — the knowledge, the evidence, the work — exists. The screen says you cannot have it. And the person who wrote the note understood, before you arrived, that this was the architecture you were sitting inside.
RELX's full political investment — including state-level lobbying, trade association dues to AAP and STM, informal influence through journal brand control over career evaluation, and the aggregate value of impact factor leverage over institutional and government decision-makers — is not captured in the $3 million federal lobbying figure. The true measure of the lobby's political reach is not calculable from public disclosures.
The internal deliberations of the 2012 House Science Committee on why no legislation followed the hearing at which Elsevier's margins were explicitly named are not in the public record. Whether industry lobbying, political calculation, or genuine disagreement about the appropriate regulatory response produced the inaction is not established from available evidence.
The long-term trajectory of the NIH zero-embargo mandate under future administrations — whether it will be maintained, weakened, or extended to other federal funders — is unknown. Federal open access policy has been subject to political revision in prior administrations. The durability of the Government Use License mechanism against future industry legal challenges has not been definitively tested in court.
The timeline on which the impact factor coordination problem resolves — if it resolves — is genuinely uncertain. DORA commitments are real. System-wide behavioral change at the scale required to displace the toll has not yet materialized. The wall runs at that threshold, as it has for thirty-three years.
Primary Sources · Post 4
- OpenSecrets federal lobbying database — RELX Group; ~$3M annual US federal lobbying under "Printing & Publishing"
- Research Works Act, H.R. 3699 (112th Congress, 2011) — introduced December 2011; withdrawn February 2012
- Cost of Knowledge boycott — Elsevier boycott campaign; 12,000+ signatories; 2012
- House Committee on Science, Space, and Technology hearing, March 2012 — federally funded research and public access; Elsevier margin testimony on record
- RELX 2025 Annual Report — STM segment operating margins 34.8%
- cOAlition S — transformative arrangement end December 2024; 2026–2030 strategy (coalition-s.org)
- NIH NOT-OD-25-101 — zero-embargo effective July 1, 2025; Government Use License
- 2 CFR 200.315 — federal Government Use License; pre-existing right in grant agreements
- Association of American Publishers — trade association representing commercial publishers in legislative proceedings
- International Association of Scientific, Technical and Medical Publishers (STM) — industry trade body
- Suber, Peter, "Open Access" (MIT Press, 2012) — comprehensive documentation of reform history and industry resistance
No comments:
Post a Comment